News Releases

Date Title
03/14/2017 Summary ToggleEnanta Announces Japanese Ministry of Health, Labour and Welfare Grants Priority Review for AbbVie’s Investigational HCV Regimen of Glecaprevir/Pibrentasvir (G/P) for the Treatment of All Major Genotypes of Chronic Hepatitis C
02/27/2017 Summary ToggleEnanta Announces CHMP Grants Positive Opinion for an Eight-Week Treatment Option with AbbVie’s VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) for Patients with Genotype 1b Chronic Hepatitis C
02/08/2017 Summary ToggleEnanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2016
02/06/2017 Summary ToggleEnanta Pharmaceuticals to Present at Two Upcoming Investor Conferences
02/02/2017 Summary ToggleEnanta Announces U.S. FDA Grants Priority Review to AbbVie’s Investigational HCV Regimen of Glecaprevir/Pibrentasvir (G/P) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6)
01/24/2017 Summary ToggleEnanta Announces EMA Grants Accelerated Assessment, Validates Marketing Authorization Application for AbbVie’s Investigational HCV Regimen of Glecaprevir/Pibrentasvir (G/P) for the Treatment of All Major Genotypes (GT1-6) of Chronic Hepatitis C
01/23/2017 Summary ToggleEnanta Pharmaceuticals to Host Conference Call on February 8 at 4:30 p.m. ET to Discuss Financial Results for its Fiscal First Quarter Ended December 31, 2016
01/09/2017 Summary ToggleEnanta Announces High SVR12 Rates Achieved in Genotype 1 Chronic HCV Infected Japanese Patients with Eight Weeks of Treatment with AbbVie’s Investigational, Pan-Genotypic, Ribavirin-free Regimen of Glecaprevir/Pibrentasvir (G/P)
01/06/2017 Summary ToggleEnanta Pharmaceuticals Announces Highlights of Business Overview and Update on its Research and Development Programs to be Presented at the 35th Annual J.P. Morgan Healthcare Conference
01/04/2017 Summary ToggleFDA Grants Fast Track Designation to Enanta’s FXR Agonist Candidate, EDP-305, for the treatment of NASH with Liver Fibrosis